To further investigate the influence of EZH2 on FGFR4 inhibitor treatment in vivo, we generated zebrafish HCC primary tumors with liver-specific overexpression of EZH2 (KRASG12V+/EZH2+). This evidence concerns the gene FGFR4 and hepatocellular carcinoma.